News

Deal Announcements

Argos Closes Series D Venture Capital Investment

Wednesday, April 25, 2012 5:33:00 AM PDT | VentureDeal Staff
Durham, North Carolina  --  Biotechnology company Argos Therapeutics has landed $25 million in series D venture capital financing.

Argos is developing a new generation of personalized cancer and infectious disease immunotherapies.

The company is backed by a large syndicate of venture capital and private equity firms and intends to use the financing to move its clinical studies forward.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1